{"prompt": "['Trelagliptin-4002', 'Page 38 of 66', 'Version 1.0', 'November 2, 2016', '9.1.11 Treatment Compliance', 'Throughout the study period, instructions for treatment will be given to subjects. If instructions were', 'given for treatment incompliance, the details will be recorded on the source document. At each visit,', 'the investigator will check with subjects the treatment compliance status with study drug or', 'comparative drug.', 'The investigator will instruct the subjects to record study drug or comparative drug usage on a', '\"Diabetes Treatment Medication Record Card*. The subjects will also be instructed to bring empty', 'sheets allowing compliance and usage to be checked along with the \"Diabetes Treatment Medication', \"Record Card*' at each visit. The treatment compliance status with the study drug or comparative\", 'drug (administration time and quantity of the study drug or comparative drug prescribed and unused)', 'will be recorded on the CRF throughout the study period.', '*. Diabetes Treatment Medication Record Card: The card contains an electronic circuit board, and', 'the times that medication is taken are electronically recorded by pressing a button when medication', 'is taken.', '9.1.12 Hospitalization for type 2 diabetes', 'The investigator will check with study subjects any hospitalization for type 2 diabetes after the first', 'administration of the study drug or comparative drug (excluding educational hospitalization without', 'worsening of diabetes). The admission-discharge date will be recorded on CRF.', '9.1.13 Contraception', 'Female subjects of childbearing potential (e.g., nonsterilized or premenopausal female subjects)', 'must use adequate contraception from signing on the informed consent throughout the study period.', 'At the time of acquisition of informed consent from an applicable study subject, signature on the', 'informed consent should be acquired only after explanation is made about what is the adequate', 'contraception and that the subject must avoid to be pregnant during the study period by use of the', 'informed consent form until the subject thoroughly understands them.', '9.1.14 Pregnancy', 'When a study subject or a partner of study subject was found to be pregnant during the study period,', 'the principal investigator or investigator notify the monitoring staff of the sponsor. The principal', 'investigator or investigator provide detailed information using the Follow-up Form for Pregnancy', 'separately wherever possible.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 39 of 66', 'Version 1.0', 'November 2, 2016', '9.1.15 Record of study subjects who are withdrawn before randomization', 'A CRF shall be created for all study subjects who have signed the consent form and withdrawn', 'before randomization.', 'The following items are to be described on the CRF.', 'Date of consent obtainment', 'Date of birth', 'Gender', 'Eligibility', 'Reason for discontinuation', 'The primary reason for withdrawal before randomization shall be recorded on the CRF according to', 'the following classification:', 'Not satisfying at least one of the inclusion criteria or meeting any of the exclusion criteria', 'Major protocol deviation', 'Lost to follow-up', 'Voluntary discontinuation (specify the reason)', 'Study termination', 'Pregnancy', 'Others (specify the reason)', 'Study subject ID codes assigned to study subjects withdrawn from the study before randomization', 'shall not be reused.', '9.1.16 Record of randomization', 'Study subjects to be randomized shall meet all of the inclusion criteria and shall not meet any of the', 'exclusion criteria according to Section 8.4. The principal investigator or investigator shall specify', 'the primary reason why the study subject cannot be randomized.', '9.2', 'Implementation time point of the tests and observation', 'The schedule for all tests, observations, and evaluations is shown in Appendix A. The principal', 'investigator or investigator shall perform the tests, observations, and evaluations at the time points', 'shown below.', '9.2.1 Screening period (Week -4)', 'After obtaining informed consent, the physical examination and tests will be performed for the', 'determining eligibility for study enrollment. The eligibility of a patient will be determined based on', 'the inclusion/exclusion criteria presented in the section 7.0. Refer to the section 9.1.16 for the', 'preparation of records on a study subject withdrawn from the study before randomization.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 40 of 66', 'Version 1.0', 'November 2, 2016', 'Tests, observations and evaluations performed at the start of the screening period (Visit 1: Day -29', 'to -1) are shown below.', 'Informed consent', 'Concomitant drugs*', 'Inclusion/ exclusion criteria', 'Comorbidity*', 'Demographic data, medical history', 'Laboratory tests (HbA1c only)', '*', \"Physical examination'\", 'DTR-QOL Questionnaire', 'Height, body weight and BMI', 'The Basic Information on Study', 'Subject (Your Basic Profile) *', '*. To be performed during from Day -29 until Day - -14.', '9.2.2 Treatment period (Week 0)', 'An eligible study subject in consequence of the tests, observations and evaluations before the start of', 'the treatment period will be randomized in accordance with the section 8.4.', 'Tests, observations and evaluations performed at the start of the screening period (Visit 2: Week 0)', 'are shown below.', 'inclusion/exclusion criteria', 'DTR-QOL Questionnaire', 'Physical examination', 'DTSQ', 'Concomitant drugs', 'The Basic Information on Study', 'Subject (Your Basic Profile)', 'Comorbidity', 'Adverse event\"', 'Laboratory tests (blood chemistry and', 'Hospitalization for type 2 diabetes', 'urinalysis)', 'Prescription of the study drug/ or', 'comparative drug', '#: To be performed after the first administration (Day 1).', '9.2.3 Treatment period (Week 4)', 'Tests, observations and evaluations performed during the treatment period (Visit 3: Week 4) are', 'shown below.', 'Physical examination', 'DTR-QOL Questionnaire', 'Concomitant drugs', 'DTSQ', 'Laboratory tests (blood chemistry and', 'The Basic Information on Study', 'urinalysis)', 'Subject (Your Basic Profile)', 'Prescription of the study drug/ or', 'Adverse event', 'comparative drug', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}